Sign In
Buy IBIO
$1.84
+0.0800 (+4.55%)
At Close: Jun 03, 2026
iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess ea
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Ac
iBio Reports Fiscal Third Quarter 2025 Financial Results
08:00am, Friday, 02'nd May 2025
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.
iBio Raises $6.2 Million Through Warrant Inducement Transaction
01:43pm, Tuesday, 29'th Apr 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
08:00am, Tuesday, 22'nd Apr 2025
In-Licensing of novel activin E antibody underscores iBio's commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases In-Licensing of novel activin E an
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days
iBio to Begin Trading on the Nasdaq Stock Exchange
04:05pm, Wednesday, 19'th Feb 2025
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on
iBio Reports Fiscal Second Quarter 2025 Financial Results
04:05pm, Monday, 10'th Feb 2025
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress.
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Reg
iBio Reports Fiscal First Quarter 2025 Financial Results
04:05pm, Tuesday, 12'th Nov 2024
Advanced myostatin program with dosing underway in non-human primate study Advanced myostatin program with dosing underway in non-human primate study
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
04:05pm, Friday, 20'th Sep 2024
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended Jun
iBio to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 03'rd Sep 2024
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenn
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
04:30pm, Monday, 12'th Aug 2024
Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead st
iBio Closes Sale of Manufacturing Facility in Texas
07:00am, Monday, 03'rd Jun 2024
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Monday, 13'th May 2024
BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported fin
